Professor Charles E. Geyer: Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer

Charles E. Geyer

Research output: Contribution to journal › Editorial › peer-review

ASJC Scopus subject areas

@article{dbf845d97e16429da9c7a5ba21f960b3,

title = "Professor Charles E. Geyer: Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer",

author = "Geyer, {Charles E.}",

year = "2016",

month = jan,

day = "1",

doi = "10.21037/cco.2016.10.06",

language = "English (US)",

volume = "5",

journal = "Chinese Clinical Oncology",

issn = "2304-3865",

publisher = "Society for Translational Medicine (STM)",

number = "5",

}

TY - JOUR

T1 - Professor Charles E. Geyer

T2 - Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer

AU - Geyer, Charles E.

PY - 2016/1/1

Y1 - 2016/1/1

UR - http://www.scopus.com/inward/record.url?scp=84998953653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998953653&partnerID=8YFLogxK

U2 - 10.21037/cco.2016.10.06

DO - 10.21037/cco.2016.10.06

M3 - Editorial

C2 - 27829284

AN - SCOPUS:84998953653

SN - 2304-3865

VL - 5

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

IS - 5

ER -